Cipla, Pfizer, Sun take hit on NLEM price cut

MUMBAI: The revision of the National List of Essential Medicines will have an impact on companies like Cipla, Pfizer and Sun pharma according to analysis done by All Indian Origin Chemists & Distributors Ltd (AIOCD Ltd) a research firm.

Cipla will lose Rs 84 crore because of the price cuts followed by Pfizer which will see an erosion of Rs 56 crore and Sun Pharma that will have an impact of Rs 42 crore, AIOCD said.

Among the therapy areas, the new NLEM list will fall mostly on anti infectives, which will have a total value loss of Rs 170 crore, followed by cardiac drugs (Rs 130 cr).

The overall patient benefit of the new list is estimated to be Rs 747 crore.

Last week the National Pharmaceutical Pricing Authority added 106 drugs to the existing 348 drugs under price control, bringing down the prices of essential medicines.